KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Revenue (2016 - 2025)

Alnylam Pharmaceuticals' Revenue history spans 17 years, with the latest figure at $1.1 billion for Q4 2025.

  • For Q4 2025, Revenue rose 84.95% year-over-year to $1.1 billion; the TTM value through Dec 2025 reached $3.1 billion, up 40.1%, while the annual FY2025 figure was $3.7 billion, 65.19% up from the prior year.
  • Revenue reached $1.1 billion in Q4 2025 per ALNY's latest filing, down from $1.2 billion in the prior quarter.
  • In the past five years, Revenue ranged from a high of $1.2 billion in Q3 2025 to a low of $30.0 million in Q1 2025.
  • Average Revenue over 5 years is $455.4 million, with a median of $327.2 million recorded in 2022.
  • Peak YoY movement for Revenue: skyrocketed 183.96% in 2023, then crashed 93.93% in 2025.
  • A 5-year view of Revenue shows it stood at $258.5 million in 2021, then rose by 29.59% to $335.0 million in 2022, then surged by 31.25% to $439.7 million in 2023, then soared by 34.9% to $593.2 million in 2024, then skyrocketed by 84.95% to $1.1 billion in 2025.
  • Per Business Quant, the three most recent readings for ALNY's Revenue are $1.1 billion (Q4 2025), $1.2 billion (Q3 2025), and $773.7 million (Q2 2025).